DOCK8 Deficiency and No Matched Donor

  • Beatriz Morillo-Gutierrez
  • Mary SlatterEmail author


  • Hematopoietic stem cell transplantation is still the only curative treatment for many primary immunodeficiencies

  • HSCT has the best outcome if performed before the development of potential comorbidities

  • Nowadays, the lack of a matched donor must not be a limitation, thanks to the availability of new techniques to avoid graft versus host disease, such as CD3+TCRαβ+/CD19+ depletion technique used here


Dedicator of cytokinesis Hematopoietic stem cell transplantation Graft versus host disease 


  1. 1.
    Su HC, Jing H, Zhang Q. DOCK8 deficiency. Ann N Y Acad Sci. 2011;1246:26–33.CrossRefGoogle Scholar
  2. 2.
    Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: insights into pathophysiology, clinical features and management. Clin Immunol. 2017;181:75–82.CrossRefGoogle Scholar
  3. 3.
    Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, Amrolia PJ, Gaspar HB, Davies EG, Friedrich W, Hoenig M, Notarangelo LD, Mazzolari E, Porta F, Bredius RG, Lankester AC, Wulffraat NM, Seger R, Gungor T, Fasth A, Sedlacek P, Neven B, Blanche S, Fischer A, Cavazzana-Calvo M, Landais P. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602–10.e1–11.CrossRefGoogle Scholar
  4. 4.
    Pira GL, Montanari SDCM, Moretta L, Manca F. Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: rationale, strategies and perspectives. Blood Rev. 2016;30:297–307.CrossRefGoogle Scholar
  5. 5.
    Slatter M, Gennery A. Approaches to the removal of T-lymphocytes to minimize graft-versus-host disease in patients with primary immunodeficiencies who do not have a matched sibling donor. Curr Opin Allergy Clin Immunol. 2017;17:414–20.CrossRefGoogle Scholar
  6. 6.
    Slatter MA, Brigham K, Dickinson AM, Harvey HL, Barge D, Jackson A, Bown N, Flood TJ, Cant AJ, Abinun M, Gennery AR. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol. 2008;121(2):361–7.CrossRefGoogle Scholar
  7. 7.
    Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B, Brescia LP, Li Pira G, Testi M, Cancrini C, Kabbara N, Carsetti R, Finocchi A, Moretta A, Moretta L, Locatelli F. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6.CrossRefGoogle Scholar
  8. 8.
    Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, Laberko A, Livshits A, Novichkova G, Maschan A. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955–62.CrossRefGoogle Scholar
  9. 9.
    Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, Rao K, Lucchini G, Silva JMF, Worth A, Barge D, Ryan D, Conn J, Cant AJ, Skinner R, Abd Hamid IJ, Flood T, Abinun M, Hambleton S, Gennery AR, Veys P, Slatter M. T-cell receptor alphabeta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141(4):1417–26.e1.CrossRefGoogle Scholar
  10. 10.
    Shah NN, Freeman AF, Su H, Cole K, Parta M, Moutsopoulos NM, Baris S, Karakoc-Aydiner E, Hughes TE, Kong HH, Holland SM, Hickstein DD. Haploidentical related donor hematopoietic stem cell transplantation for dedicator-of-cytokinesis 8 deficiency using post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2017;23(6):980–90.CrossRefGoogle Scholar
  11. 11.
    Teschner D, Distler E, Wehler D, Frey M, Marandiuc D, Langeveld K, Theobald M, Thomas S, Herr W. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant. 2014;49(1):138–44.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Translational Paediatrics and Infectious Diseases UnitSantiago de Compostela University HospitalSantiago de CompostelaSpain
  2. 2.Department of Paediatric ImmunologyGreat North Children’s Hospital, Royal Victoria InfirmaryNewcastle upon TyneUK
  3. 3.Institute of Cellular MedicineNewcastle UniversityNewcastle upon TyneUK

Personalised recommendations